Related Experiment Videos
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter
Matthew R Wilson1, Katharine L Lewis2, Amy A Kirkwood3
1Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Summary
High-dose methotrexate (HD-MTX) does not significantly reduce central nervous system (CNS) relapse in ultra high-risk (UHR) large B-cell lymphoma (LBCL) patients. This large international study found no meaningful benefit of HD-MTX prophylaxis for most UHR patients.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Large B-cell lymphoma (LBCL) treatment guidelines recommend high-dose methotrexate (HD-MTX) for central nervous system (CNS) relapse prophylaxis in ultra high-risk (UHR) patients.
- Robust data specifically evaluating HD-MTX efficacy in UHR subgroups are lacking, leading to ongoing controversy regarding its use.
Purpose of the Study:
- To investigate the impact of HD-MTX on CNS relapse rates in LBCL patients classified as UHR.
- To provide evidence-based recommendations for CNS prophylaxis strategies in this specific patient population.
Main Methods:
- A combined cohort of 1,923 UHR LBCL patients from two retrospective analyses was utilized.
- Patients received either HD-MTX or no HD-MTX for CNS prophylaxis.
- The primary outcome was the 3-year cumulative incidence of CNS relapse, with additional landmark analyses performed.
Main Results:
- No significant difference in the 3-year CNS relapse rate was observed between patients who received HD-MTX (8.1%) and those who did not (9.3%).
- Multivariable analyses, including those adjusted for baseline characteristics, confirmed no significant difference in CNS relapse rates (adjusted HR, 1.13).
- Analyses of isolated CNS relapse and landmark analyses also showed no significant benefit of HD-MTX.
Conclusions:
- This study, the largest international comparative dataset for UHR LBCL patients, indicates that HD-MTX does not significantly reduce CNS relapse.
- The findings suggest that HD-MTX prophylaxis offers no meaningful benefit for the majority of UHR LBCL patients.
- Further research may be warranted to identify specific UHR subgroups that could potentially benefit from HD-MTX or alternative prophylactic strategies.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...